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Abstract
Solitary bone plasmacytomas are part of a
wide range of monoclonal neoplasms that
share a common progenitor in the B lympho-
cyte lineage. In their particular case, a single
bone lesion is found, most frequently on the
axial skeleton, having evidence of no other
osteolytic lesions or systemic involvement.
Diagnosis can sometimes prove to be difficult
as they are rare tumors, occurring in 3 to 5%
(up to 10% in some series) of patients with
plasma cell neoplasms, with important consid-
erations regarding the differential diagnosis.
We report a case of a solitary bone plasmacy-
toma, found on the ala of the left ilium of a
patient during a routine consult due to hip
pain.
Case Report
A 54-year-old woman, with medical history
of hypertension, type II diabetes, dyslipidemia
and osteoarticular degenerative disease of the
spine already being studied at our institution,
was admitted to our emergency department
complaining of bilateral hip pain following a
minor trauma. Radiographic studies per-
formed showed no fractures or apparent bone
lesions. One week later, after having sustained
a fall from her own height, the patient was
admitted again to the emergency department.
At this time, and having worsening of the com-
plaints, another set of radiographic studies
were performed and showed fracture of the
right ischiopubic and iliopubic rami, as well as
a large osteolytic lesion on the left ilium ala
(Figure 1). Conservative course of treatment
was decided for the fractures and the patient
was referenced to the outpatient consult at our
institution to have the lesion studied. A CT was
performed and confirmed the lesion suspected
on the x-rays. Besides the iliopubic and
ischiopubic fractures on the right pelvis
already known, MRI showed a solid large mass
extending from the left ilium to the left sacroil-
iac joint, with approximately 13.4×13×8.9 cen-
timeters wide, with necrotic areas (Figure 2).
Bone scintigraphy couldnt characterize better
the lesion but excluded other bone lesions.
The patient was referenced to the hemato-
oncology specialist. Bone marrow biopsy
showed no involvement by clonal cells.
Histopathologic studies confirmed the diagno-
sis of solitary bone plasmacytoma of the pelvis
(Figure 3) and radiotherapy cycle was initiat-
ed.
Discussion
Plasmacytomas take part on a vast
group of clonal disorders that affect plasma
cells. These disorders also involve other types
of neoplasms that, due their common origin,
make their characterization difficult.1 The site
of tumor and the presence of systemic mani-
festations can usually, but not always, point
the type of tumor present. Solitary plasmacy-
tomas can be classified into 2 groups accord-
ing to their location: solitary bone plasmacy-
tomas (SBP) – affecting the skeletal system –
and extramedullary plasmacytoma (EMP)
affecting virtually every lymphoid tissue, being
more frequent in upper respiratory tract.1-4
Over the last decades, clinical data recognized
specifically SBP and other unusual monoclonal
gammapathies like EMP as different identi-
ties, with proper clinical presentation, specific
diagnostic criteria, treatment strategies and
prognosis.1,5,6 Nonetheless, clinical aspects
overlap, thus making directed diagnostic and
therapeutic strategies difficult. Importantly,
SBP are more prone to evolve to multiple
myeloma (MM) than EMP, thus having a poor-
er prognosis.7
Population-based data about SBP are sparse
although all studies refer to them as uncom-
mon tumors, occurring in 3-5% of patients
with plasma cell neoplasms (in some western
series up to 10%).6 Comparing to MM, SBP are
sixteen times less frequent and the incidence
of EMP is 40% lower than SBP.8 Regarding SBP,
males are twice likely to be more affected than
females (65% vs. 35%) and the median age of
presentation is a decade younger than that of
patients with MM (55 vs. 65 years).1,9,10 People
older than 60 years old are more affected (up to
9 times more),8 although there is also evidence
that younger people can be affected if preced-
ing trauma.2 One observational study also tried
to make conclusions about the influence of
race and plasmacytomas, and found that
Whites had intermediate risk comparing to
Black (higher risk) and Asians, although this
finding was not statistically significant and
more studies would be necessary to make con-
siderations about this relationship.8
Clinically, at presentation, the most com-
mon symptom is pain at the site of the bone
lesion, due to destruction,1,9 although some-
times asymptomatic disease can be found in
routine radiographic tests or when soft tissue
extension of the lesion produces a palpable
mass. Regarding the site of lesion, involve-
ment of the axial skeleton is more likely than
the appendicular skeleton (83% vs 17%)8 and
one study also found that axial presentation of
the disease was more likely to occur in
younger patients than cases arising from the
appendicular skeleton (64 vs 69 years).8 As
these tumors target areas of marrow with the
most active hematopoiesis, the order of fre-
quency on which location they are typically
found is the vertebrae, ribs, skull, pelvis,
femur, clavicle, and scapula.11 Thoracic verte-
brae are more commonly involved than lumbar
or cervical vertebrae. Thus, severe back pain or
spinal cord compression or a pathological frac-
ture may be the presenting complaint.3
Nonetheless, another study found that in 20%
of patients with SBP, a rib, the sternum, the
clavicle, or the scapula was involved.1 More
uncommon is the involvement of the dstal
appendicular skeleton, where disease below
the knees or elbows is rare.1
In face of clinical suspicion, some criteria
must be followed to make the diagnosis: i) sin-
gle area of bone destruction due to clonal plas-
ma cells; ii) normal marrow without clonal dis-
ease; iii) normal results on a skeletal survey
and magnetic resonance imaging of the spine,
pelvis, proximal femora, and humeri; iv) no
anemia, hypercalcemia, or renal impairment
attributable to myeloma; v) absent or low
serum or urinary level of monoclonal protein
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and preserved levels of uninvolved
immunoglobulins,9 although recent criteria
may include a small M-component that can be
present in serum or urine in 50% of patients.1
Besides the above criteria of diagnosis,
imaging studies play an important role in the
diagnostic, treatment considerations and prog-
nostic aspects. A recent retrospective series of
10 patients with histological confirmation of
SBP of the pelvis, analyzed the correlation
between CT, MRI and histopathologic
features.10 Although few patients were ana-
lyzed (with 50% cases affecting the ilium), this
study found a correlation between imaging
characteristics and histopathologic grade, with
superiority of CT on characterizing the type of
bone destruction and concordance with histol-
ogy findings, and MRI with better value as a
prognostic method for reexamination after
radiotherapy. 
Course of treatment has been discussed
over the last decades, with consensus of local
radiotherapy as first line option. Correct dose
of radiation has yet to be established, although
most studies found good response with local
radiotherapy at doses of 3500-4500 cGy (4000
cGy for vertebral lesions). Higher doses can
produce toxic effects without proved therapeu-
tical benefit.9 Monitorization of M-protein
(when present) was proposed as a marker of
therapy response as it could predict the pro-
gression to MM,13 although many patients
maintain long-term stability even with M-pro-
tein persistency after radiotherapy.1,6,9 Imaging
methods, particularly MRI can have a role in
evaluating therapy response. Besides radio-
therapy, some patients (particularly those with
vertebral involvement), can show neurological
impairment due to vertebra instability or
pathological factures with compression of the
spinal chord and/or its roots, and may benefit
of surgical fixation.9 Adjuvant chemotherapy
has been discussed, with some authors
defending less progression rate to MM,14
although others found no other differences
either than a lesser time to MM diagnosis.15
However, most studies did not find beneficial
effects of adjuvant chemotherapy, and in fact
can raise problems with systemic toxicity and
appearance of resistant clone cells.16
Age is an important prognostic factor. Older
age at the time of diagnosis has a striking
effect on 5 year-survival according to most
studies. Patients younger than 60 years appear
to have a better prognosis. Size of tumor (soli-
tary plasmacytomas >5 cm) appear to have a
greater conversion to MM.17 Progression to
MM, can occur (being this rate increased in
advanced age, especially in SBP when compar-
ing to EMP), although this is not common,
especially if radiotherapy provides good
response. Indeed radiotherapy may prevent
local relapse in 90% of patients,18 although it
has been described that progression to overt
MM can occur in 50% of patients but taking
approximately 15 years to do so.1 When pro-
gression occurs earlier on the course of dis-
ease, subclinical myeloma should be suspected
as present at the time of the initial diagnosis.9
On the other hand recurrent solitary plasmacy-
tomas (other bone lesions with no evidence of
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Figure 2. Magnetic resonance imaging: arrows pointing to solid large mass extending
from the left ilium to the left sacroiliac joint, with approximately 13.4×13×8.9 cm wide.
A) T1-weighted coronal view; B) T2-weighted coronal view; C) T1-weighted axial view;
D) T2-weighted axial view; E) T1-weighted sagittal view.
Figure 3. Histologic features of plasmacytoma. A) Sheets of well-differentiated plasma
cells (Hematoxylin and eosin 400×). B) CD 138+ staining (400×). C) Absence of kappa
light-chain expression (400×) D) lambda light-chain positivity (400×).
Figure 1. Radiography: small arrows show-
ing fracture of the right ischiopubic and
iliopubic rami; large arrow: large osteolytic
lesion on the left ilium ala.
MM) can occur in up to 5-10% of patients.
Reported in most series, 10-year survival is
about 50%, being 25-40% of patients disease
free at that time.
Recent studies did not found survival differ-
ences regarding location (axial vs. appendicu-
lar skeleton), sex, or race.8
Conclusions
Solitary bone plasmacytomas are rare
tumors, and their diagnosis can be challenging
even by experienced professionals. Clinical
presentation can often mislead on the pursuit
of the correct diagnosis. Pelvic involvement by
these tumors has been rarely described in the
literature. The presentation of this case should
make awareness on the occurrence of these
neoplasms for prompt diagnosis and initiation
of treatment. 
References
1. International Myeloma Working Group.
Criteria for the classification of monoclon-
al gammopathies, multiple myeloma and
related disorders: a report of the
International Myeloma Working Group. Br
J Haematol 2003;121:749.
2. Pasch W, Zhao X, Rezk SA. Solitary plasma-
cytoma of the bon involving young individ-
uals, is there a role for preceding trauma?
Int J Clin Exp Pathol 2012;5:463-7.
3. Kilciksiz S, Karakoyun-Celik O, Agaoglu
FY, Haydaroglu A. A review for solitary
plasmacytoma of bone and extramedullary
plasmacytoma. Sci World J 2012;2012:
895765.
4. Soutar R, Lucraft H, Jackson G, et al.
Guidelines on the diagnosis and manage-
ment of solitary plasmacytoma of bone and
solitary extramedullary plasmacytoma.
Clin Oncol (R Coll Radiol) 2004;16:405-13.
5. Corwin J, Lindberg RD. Solitary plasmacy-
toma of bone vs. extramedullary plasmacy-
toma and their relationship to multiple
myeloma. Cancer 1979;43:1007-13.
6. Shih LY, Dunn P, Leung WM, et al.
Localised plasmacytomas in Taiwan: com-
parison between extrameduliary plasma-
cytoma and solitary plasmacytoma of bone.
Br J Cancer 1995;71:128-33.
7. Suh YG, Suh CO, Kim JS, et al.
Radiotherapy for solitary plasmacytoma of
bone and soft tissue: outcomes and prog-
nostic factors. Ann Hematol 2012;91:1785-
93.
8. Graça MD, Ola L,  Katherine AM, et al.
Plasmacytoma of bone, extramedullary
plasmacytoma, and multiple myeloma:
Incidence and survival in the United
States, 1992-2004. Br J Haematol
2009;144:86-94.
9. Dimopoulos MA, Moulopoulos LA,
Maniatis A, Alexanian R. Solitary plasma-
cytoma of bone and asymptomatic multiple
myeloma. Blood 2000;96:2037-44.
10. Wang Y, Zhu XL, Peeroo MW, et al. Pelvic
solitary plasmacytoma: computed tomogra-
phy and magnetic resonance imaging find-
ings with histopathologic correlation.
Korean J Radiol 2015;16:146-53.
11. Jaffe ES, Harris NL, Stein H, Vardiman JW,
eds. World Health Organization classifica-
tion of tumours. Pathology and genetics of
tumours of the haematopoietic and lym-
phoid tissues. Geneva: WHO; 2001.
12. Burt M, Karpeh M, Ukoha O, et al. Medical
tumors of the chest wall: solitary plasma-
cytoma and Ewing’s sarcoma. J Thorac
Cardiovasc Surg 1993;105:89-96.
13. Wilder RB, Ha CS, Cox JD, et al.
Persistence of myeloma protein for more
than one year after radiotherapy is an
adverse prognostic factor in solitary plas-
macytoma of bone. Cancer 1994:1532-7.
14. Mayr NA, Wen BC, Hussey DH, et al. The
role of radiation therapy in the treatment
of solitary plasmacytomas. Radiother
Oncol 1990;17:293-303.
15. Holland J, Trenkner DA, Wasserman TH,
Fineberg B. Plasmacytoma. Treatment
results and conversion to myeloma.
Cancer 1992;69:1513-7.
16. Delauche-Cavallier MC, Laredo JD, Wybier
M, et al. Solitary plasmacytoma of the
spine. Long-term clinical course. Cancer
1988;61:1707-14.
17. Tsang RW, Gospodarowicz MK, Pintilie M,
et al. Solitary plasmacytoma treated with
radiotherapy: impact of tumor size on out-
come. Int J Radiat Oncol Biol Phys
2001;50:113-20.
18. Wei A, Juneja S. Bone marrow immuno-
histology of plasma cell neoplasms. J Clin
Pathol 2003;56:406-11. 
                                                                                                                    Case Report
                                                                                  [Rare Tumors 2016; 8:6306]                                                                 [page 41]
